| P/E (FY) | — | Sales (TTM) | €7.21B |
| Earnings (TTM) | €156.9M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | — | Trading Days | 3807 |
| 52W High | 11.14 |
| 52W Low | 6.96 |
| % Off High | −28.19% |
| YTD | −13.29% | 1Y | −18.31% |
| 3Y | −22.24% | 5Y | −46.13% |
| 10Y | −44.72% | Since incept. (ann.) | 1.93% |
| Ann. Volatility (1Y) | 31.87% | Ann. Volatility (3Y) | 51.42% |
| Sharpe (1Y) | −0.49 | Sharpe (3Y) | 0.13 |
| Max Drawdown (1Y) | −34.08% | Max Drawdown (3Y) | −52.68% |
| Beta (3Y, vs SPY) | 0.93 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.15T | 53.2 |
| JNJ | JOHNSON & JOHNSON | $642.79B | 24.2 |
| ONC | BeOne Medicines Ltd. | $477.60B | 1739.3 |
| ABBV | AbbVie Inc. | $465.02B | 111.5 |
| MRK | Merck & Co., Inc. | $325.57B | 18.1 |
| ABT | ABBOTT LABORATORIES | $186.84B | 28.8 |
| PFE | PFIZER INC | $143.91B | 18.6 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.88B | 18.4 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $124.46B | 32.0 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.32B | 16.8 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.25B | 123.8 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $36.88B | 26.2 |
